Total Payments
$401,952
2024 Payments
$38,282
Companies
56
Transactions
1,478
Medicare Patients
76,461
Medicare Billing
$3.3M
Payment Breakdown by Category
Other$359,775 (89.5%)
Food & Beverage$29,344 (7.3%)
Travel$9,043 (2.2%)
Consulting$3,275 (0.8%)
Education$514.92 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $350,275 | 188 | 87.1% |
| Food and Beverage | $29,344 | 1,237 | 7.3% |
| Honoraria | $9,500 | 5 | 2.4% |
| Travel and Lodging | $9,043 | 23 | 2.2% |
| Consulting Fee | $3,275 | 8 | 0.8% |
| Education | $514.92 | 17 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $88,325 | 144 | $0 (2024) |
| Amgen Inc. | $69,348 | 358 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $54,917 | 119 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $35,651 | 49 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $25,472 | 232 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $23,131 | 73 | $0 (2024) |
| Esperion Therapeutics, Inc. | $20,532 | 38 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $16,279 | 38 | $0 (2023) |
| Lilly USA, LLC | $14,624 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $13,226 | 50 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,282 | 193 | Amgen Inc. ($13,231) |
| 2023 | $35,754 | 213 | Boehringer Ingelheim Pharmaceuticals, Inc. ($12,160) |
| 2022 | $33,911 | 208 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,972) |
| 2021 | $41,203 | 147 | Boehringer Ingelheim Pharmaceuticals, Inc. ($11,687) |
| 2020 | $34,657 | 92 | Amgen Inc. ($9,149) |
| 2019 | $57,911 | 184 | Janssen Pharmaceuticals, Inc ($20,143) |
| 2018 | $64,903 | 210 | Janssen Pharmaceuticals, Inc ($20,240) |
| 2017 | $95,331 | 231 | Janssen Pharmaceuticals, Inc ($30,353) |
All Payment Transactions
1,478 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,825.00 | General |
| Category: DIABETES | ||||||
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,825.00 | General |
| Category: DIABETES | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $10.71 | General |
| Category: Cardiovascular | ||||||
| 12/16/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/13/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: Cardio-renal | ||||||
| 12/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $122.48 | General |
| Category: Cardiology | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,040.00 | General |
| Category: DIABETES | ||||||
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: Obesity | ||||||
| 12/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Cardio-renal | ||||||
| 11/25/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/22/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $19.60 | General |
| Category: Cardiovascular | ||||||
| 11/22/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $12.66 | General |
| 11/20/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: Genetic Disease | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Cardio-renal | ||||||
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $19.04 | General |
| Category: Cardiovascular | ||||||
| 11/05/2024 | CARDIVA MEDICAL, INC. | CARDIVA VASCADE MVP VVCS 6-12F (Device) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: DEVICES | ||||||
| 11/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: DIABETES | ||||||
| 11/01/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $10.39 | General |
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $12.55 | General |
| Category: Cardiovascular | ||||||
| 10/28/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,040.00 | General |
| Category: DIABETES | ||||||
| 10/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $7.62 | General |
| Category: Cardiology | ||||||
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: DIABETES | ||||||
| 10/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 18,603 | 38,291 | $5.6M | $936,519 |
| 2022 | 57 | 18,521 | 33,609 | $5.2M | $825,003 |
| 2021 | 53 | 19,732 | 28,478 | $5.1M | $786,229 |
| 2020 | 54 | 19,605 | 27,264 | $5.1M | $713,035 |
Total Patients
76,461
Total Services
127,642
Medicare Billing
$3.3M
Procedure Codes
229
All Medicare Procedures & Services
229 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 2,264 | 3,764 | $1.3M | $304,997 | 23.5% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 23 | 11,076 | $143,306 | $103,733 | 72.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 348 | 1,426 | $185,380 | $51,555 | 27.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 744 | 768 | $1.5M | $38,261 | 2.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 2,473 | 4,075 | $244,500 | $38,083 | 15.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 667 | 687 | $247,263 | $36,671 | 14.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 253 | 502 | $97,388 | $30,156 | 31.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 247 | 748 | $103,224 | $26,396 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 229 | 229 | $102,821 | $24,802 | 24.1% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 1,366 | 1,796 | $98,780 | $23,520 | 23.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 402 | 402 | $120,028 | $23,201 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 148 | 163 | $68,639 | $20,844 | 30.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 1,558 | 2,268 | $36,288 | $19,008 | 52.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 563 | 572 | $99,672 | $18,728 | 18.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 308 | 334 | $81,496 | $18,348 | 22.5% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 69 | 399 | $28,728 | $17,050 | 59.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 1,231 | 1,620 | $56,700 | $16,715 | 29.5% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 202 | 212 | $335,251 | $16,295 | 4.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 111 | 115 | $42,205 | $11,266 | 26.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 913 | 1,162 | $37,184 | $8,817 | 23.7% |
| 83880 | Natriuretic peptide (heart and blood vessel protein) level | Office | 2023 | 159 | 201 | $22,923 | $7,732 | 33.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 493 | 500 | $50,000 | $7,686 | 15.4% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 69 | 398 | $27,064 | $7,320 | 27.0% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 104 | 104 | $25,385 | $6,438 | 25.4% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 351 | 382 | $26,358 | $6,288 | 23.9% |
About Dr. Steven Gubin, MD
Dr. Steven Gubin, MD is a Cardiovascular Disease healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497847867.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Gubin, MD has received a total of $401,952 in payments from pharmaceutical and medical device companies, with $38,282 received in 2024. These payments were reported across 1,478 transactions from 56 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($350,275).
As a Medicare-enrolled provider, Gubin has provided services to 76,461 Medicare beneficiaries, totaling 127,642 services with total Medicare billing of $3.3M. Data is available for 4 years (2020–2023), covering 229 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Memphis, TN
- Active Since 09/29/2006
- Last Updated 06/25/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1497847867
Products in Payments
- XARELTO (Drug) $88,433
- JARDIANCE (Drug) $69,172
- Repatha (Biological) $68,612
- PRALUENT (Drug) $35,518
- ENTRESTO (Drug) $24,848
- FARXIGA (Drug) $22,303
- NEXLIZET (Drug) $19,997
- ELIQUIS (Drug) $16,684
- PRALUENT ALIROCUMAB INJECTION (Biological) $15,149
- Ranexa (Drug) $12,857
- Inpefa (Drug) $6,535
- OPTIMIZER (Device) $4,457
- Optimizer (Device) $1,716
- PRALUENT (Biological) $1,107
- LEQVIO (Drug) $623.79
- BRILINTA (Drug) $604.06
- Corlanor (Drug) $577.79
- NEXLETOL (Drug) $534.75
- COBALT DR MRI SURESCAN (Device) $527.96
- Vascepa (Drug) $457.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Memphis
Dmitry Yaranov, Md, MD
Cardiovascular Disease — Payments: $600,772
Cardiovascular Disease $600,772
Frank Mcgrew, Md, MD
Cardiovascular Disease — Payments: $231,282
Cardiovascular Disease $231,282
Dwight Dishmon, Md, MD
Cardiovascular Disease — Payments: $210,097
Cardiovascular Disease $210,097
Claro Diaz, Md, MD
Cardiovascular Disease — Payments: $174,401
Cardiovascular Disease $174,401
Stevan Himmelstein, Md, MD
Cardiovascular Disease — Payments: $77,954
Cardiovascular Disease $77,954
Dr. Ikechukwu Ifedili, Md, MD
Cardiovascular Disease — Payments: $74,694
Cardiovascular Disease $74,694